Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma [0.03%]
儿童、青少年和年轻成人非霍奇金淋巴瘤的生物病理学
Megan S Lim,Michelle Foley,Lara Mussolin et al.
Megan S Lim et al.
Mature non-Hodgkin lymphomas (NHL) in the childhood, adolescent and young adult (CAYA) population are rare and exhibit unique clinical, immunophenotypic and genetic characteristics. Application of large-scale unbiased genomic and proteomic ...
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults [0.03%]
儿童、青少年和年轻成人霍奇金淋巴瘤的诊断和治疗
Jennifer A Belsky,Jessica Hochberg,Lisa Giulino-Roth
Jennifer A Belsky
Advances in the management of Hodgkin lymphoma in children, adolescents and young adult have resulted in survival outcomes exceeding 90%. The risk of late toxicity, however, remains a significant concern for survivors of HL and the focus of...
Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma [0.03%]
儿童、青少年和年轻成人非霍奇金淋巴瘤的细胞及体液免疫治疗
Yaya Chu,Aliza Gardenswartz,Caroline Diorio et al.
Yaya Chu et al.
The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately needed for this poo...
Isabelle Durand-Zaleski
Isabelle Durand-Zaleski
Health economics is about providing the population with the maximum health possible under budget constraint. The most common method to present the result of an economic evaluation is the calculation of the incremental cost-effectiveness rat...
Ana C Xavier,Ritsuro Suzuki,Andishe Attarbaschi
Ana C Xavier
Mature B-cell lymphomas, (B- or T-cell) lymphoblastic lymphomas (LBL), and anaplastic large cell lymphoma (ALCL) correspond to about 90% of all non-Hodgkin lymphoma (NHL) cases occurring in children and adolescents. The remaining 10% encomp...
Consolidation chemotherapy in AML: Are we playing with a full deck of cards? [0.03%]
急性髓系白血病中的巩固化疗：我们已经掌握了全部的治疗手段吗？
Richard M Stone
Richard M Stone
The safe diminution of leukemic cell numbers to a level such that the patient will not succumb to their disease has been an achievable, yet often elusive goal in AML. Disease heterogeneity based both on biological features as well as on pat...
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML [0.03%]
如何干预以减轻AML移植后复发？减轻AML移植后复发的策略
Jonathan A Gutman
Jonathan A Gutman
Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative approach for patients with acute myeloid leukemia (AML), relapse is a common occurrence. Several strategies, such as choice of conditioning regimen, donor...
Rafael Bejar
Rafael Bejar
Measurable residual disease in acute lymphoblastic leukemia: How low is low enough? [0.03%]
急性淋巴细胞白血病中的可测量残留病灶：多低才算低？
Aaron C Logan
Aaron C Logan
Quantification of measurable residual disease (MRD) in acute lymphoblastic leukemia (ALL) is a well-established clinical tool used to risk stratify patients during the course of chemotherapy, immunotherapy, and/or transplant therapy. As tec...